In vitro activity of aztreonam-avibactam against enterobacteriaceae and pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Karlowsky, James A ^a   Kazmierczak, Krystyna M ^b   De Jonge, Boudewijn L M ^c,d   Hackel, Meredith A ^b   Sahm, Daniel F ^b   Bradford, Patricia A ^c,e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Division of Microbiology   (United States)

^c ASTRAZENECA   (United Kingdom)

^d PFIZER INC   (United States)

^e Antimicrobial Development Specialists LLC   (United States)

Author keywords

Aztreonam avibactam; Gram negative bacteria; Metallo lactamase; Surveillance studies

Indexed keywords

ANTIINFECTIVE AGENT; AVIBACTAM; AZABICYCLO DERIVATIVE; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; MEROPENEM; THIENAMYCIN DERIVATIVE;

DRUG EFFECTS; ENTEROBACTERIACEAE; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 85028339511     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00472-17     Document Type: Article

References (36)

1. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo--lactamases, the quiet before the storm? Clin Microbiol Rev 18:306–325. https://doi.org/10.1128/CMR.18.2.306-325.2005.
2. Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. 2015. In vitro susceptibility of characterized -lactamase-producing strain tested with avibactam combinations. Antimicrob Agents Chemother 59:1789 –1793. https://doi.org/10.1128/AAC.04191-14.
3. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390 –394. https://doi.org/10.1128/AAC.00756-10.
4. Pérez A, Canle D, Latasa C, Poza M, Beceiro A, del Mar Tomás M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G. 2007. Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. Antimicrob Agents Chemother 51:3247–3253. https://doi.org/10.1128/AAC.00072-07.
5. Adler M, Anjum M, Andersson DI, Sandegren L. 2016. Combinations of mutations in envZ, ftsI, mrdA, acrB, and acrR can cause high-level carbapenem resistance in Escherichia coli. J Antimicrob Chemother 71: 1188–1198. https://doi.org/10.1093/jac/dkv475.
6. Queenan AM, Bush K. 2007. Carbapenemases: the versatile -lactamases. Clin Microbiol Rev 20:440 – 458. https://doi.org/10.1128/CMR.00001-07.
7. Bradford PA. 2001. Extended-spectrum -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933–951. https://doi.org/10.1128/CMR.14.4.933-951.2001.
8. Rafailidis PI, Falagas ME. 2014. Options for treating carbapenem resistant Enterobacteriaceae. Curr Opin Infect Dis 27:479 – 483. https://doi.org/10.1097/QCO.0000000000000109.
9. Biedenbach DJ, Kazmierczak KM, Bouchillon SK, Sahm DF, Bradford PA. 2015. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother 59:4239 – 4248. https://doi.org/10.1128/AAC.00206-15.
10. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Wakup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non--lactam -lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663–11668. https://doi.org/10.1073/pnas.1205073109.
11. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Curand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D -lactamases. J Biol Chem 288:27960–27971. https://doi.org/10.1074/jbc.M113.485979.
12. Giani T, Cannatelli A, Di Pilato V, Testa R, Nichols WW, Rossolini GM. 2016. Inhibitory activity of avibactam against selected -lactamases expressed in an isogenic Escherichia coli strain. Diagn Microbiol Infect Dis 86:83– 85. https://doi.org/10.1016/j.diagmicrobio.2016.03.002.
13. Lahiri SD, Johnstone M, Ross PL, McLaughlin R, Olivier NB, Alm RA. 2014. Avibactam and class C -lactamases: mechanisms of inhibition, conservation of binding pocket and implications for resistance. Antimicrob Agents Chemother 58:5704–5713. https://doi.org/10.1128/AAC.03057-14.
14. Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. 2016. Multiyear, multinational survey of the incidence and global distribution of metallo--lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:1067–1078. https://doi.org/10.1128/AAC.02379-15.
15. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; 27th informational supplement. CLSI document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New -lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835–1846. https://doi.org/10.1128/AAC.00826-13.
18. Papp-Wallace KM, Bonomo RA. 2016. New -lactamase inhibitors in the clinic. Infect Dis Clin North Am 30:441–464. https://doi.org/10.1016/j.idc.2016.02.007.
19. ClinicalTrials.gov. 2016. A study to investigate the safety and tolerability of aztreonam-avibactam (ATM-AVI). Registration no. NCT02655419. https://clinicaltrials.gov/ct2/show/NCT02655419?termNCT02655419&rank 1. Accessed 19 October 2016.
20. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. https://doi.org/10.1086/595011.
21. World Health Organization. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland. http://www.who.int/drugresistance/documents/surveillancereport/en/.
22. Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, Li H, Chen H, He W, Wang Q, Wang H. 2014. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 58:1774–1778. https://doi.org/10.1128/AAC.02123-13.
23. Testa R, Cantón R, Giani T, Morosini MI, Nichols WW, Seifert H, Stefanik D, Rossolini GM, Nordmann P. 2015. In vitro activity of ceftazidime, ceftaroline, and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents 45:641–646. https://doi.org/10.1016/j.ijantimicag.2014.12.033.
24. Dupont H, Gaillot O, Goetgheluck A-S, Plassart C, Emond J-P, Lecuru M, Gaillard N, Derdouri S, Lemaire B, Girard de Courtilles M, Cattoir V, Mammeri H. 2015. Molecular characterization of carbapenem-nonsusceptible enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime-avibactam and aztreonam-avibactam combinations. Antimicrob Agents Chemother 60:215–221. https://doi.org/10.1128/AAC.01559-15.
25. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. Antimicrob Agents Chemother 59:7842–7846. https://doi.org/10.1128/AAC.02019-15.
26. Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA. 2016. Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60:4490–4500. https://doi.org/10.1128/AAC.00107-16.
27. Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF. 2015. Correlation of -lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother 60:1385–1392. https://doi.org/10.1128/AAC.01870-15.
28. Alm RA, Johnstone MR, Lahiri SD. 2015. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 70:1420 –1428. https://doi.org/10.1093/jac/dku568.
29. Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA. 2015. Avibactam and inhibitor-resistant SHV -lactamases. Antimicrob Agents Chemother 59:3700–3709. https://doi.org/10.1128/AAC.04405-14.
30. Lahiri SD, Bradford PA, Nichols WW, Alm RA. 2016. Structural and sequence analysis of class A -lactamases with respect to avibactam inhibition: impact of -loop variations. J Antimicrob Chemother 71: 2848–2855. https://doi.org/10.1093/jac/dkw248.
31. Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. 2015. Variants of -lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother 59:3710–3717. https://doi.org/10.1128/AAC.04406-14.
32. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:3322–3327. https://doi.org/10.1128/AAC.44.12.3322-3327.2000.
33. Pfizer Inc. 2016. Tygacil. U.S. FDA product information. Pfizer, Inc., Col-legeville, PA.
34. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2017. Clinical breakpoints. http://www.eucast.org/clinical_breakpoints.
35. Lob S, Kazmierczak K, Badal R, Hackel M, Johnson A, Bouchillon S, Biedenbach D, Sahm D. 2015. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother 59:3606 –3610. https://doi.org/10.1128/AAC.05186-14.
36. Nichols WW, de Jonge BLM, Kazmierczak KM, Karlowsky JA, Sahm DF. 2016. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743–4749. https://doi.org/10.1128/AAC.00220-16.